Cathay Biotech Inc.
688065.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CN¥2,957,912 | CN¥2,114,175 | CN¥2,441,104 | CN¥2,363,483 |
| % Growth | 39.9% | -13.4% | 3.3% | – |
| Cost of Goods Sold | CN¥2,121,472 | CN¥1,534,947 | CN¥1,611,903 | CN¥1,526,275 |
| Gross Profit | CN¥836,440 | CN¥579,227 | CN¥829,201 | CN¥837,207 |
| % Margin | 28.3% | 27.4% | 34% | 35.4% |
| R&D Expenses | CN¥233,339 | CN¥189,128 | CN¥187,715 | CN¥133,531 |
| G&A Expenses | CN¥167,428 | CN¥183,412 | CN¥187,146 | CN¥133,266 |
| SG&A Expenses | CN¥222,005 | CN¥221,614 | CN¥232,275 | CN¥175,115 |
| Sales & Mktg Exp. | CN¥54,577 | CN¥38,202 | CN¥45,129 | CN¥41,848 |
| Other Operating Expenses | -CN¥170,465 | -CN¥285,810 | -CN¥299,073 | -CN¥194,789 |
| Operating Expenses | CN¥284,879 | CN¥124,932 | CN¥120,917 | CN¥113,857 |
| Operating Income | CN¥551,561 | CN¥454,295 | CN¥708,284 | CN¥723,350 |
| % Margin | 18.6% | 21.5% | 29% | 30.6% |
| Other Income/Exp. Net | -CN¥3,546 | -CN¥5,371 | -CN¥12,292 | CN¥1,098 |
| Pre-Tax Income | CN¥548,015 | CN¥448,925 | CN¥695,992 | CN¥724,449 |
| Tax Expense | CN¥73,426 | CN¥40,389 | CN¥83,337 | CN¥90,937 |
| Net Income | CN¥488,962 | CN¥366,524 | CN¥553,266 | CN¥594,719 |
| % Margin | 16.5% | 17.3% | 22.7% | 25.2% |
| EPS | 0.84 | 0.63 | 0.95 | 1.43 |
| % Growth | 33.3% | -33.7% | -33.6% | – |
| EPS Diluted | 0.84 | 0.63 | 0.95 | 1.43 |
| Weighted Avg Shares Out | 582,098 | 581,785 | 582,385 | 415,583 |
| Weighted Avg Shares Out Dil | 582,098 | 581,785 | 582,385 | 415,583 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥160,755 | CN¥219,771 | CN¥236,776 | CN¥213,308 |
| Interest Expense | CN¥33,475 | CN¥37,872 | CN¥24,625 | CN¥16,292 |
| Depreciation & Amortization | CN¥315,920 | CN¥285,715 | CN¥265,122 | CN¥168,535 |
| EBITDA | CN¥679,846 | CN¥451,263 | CN¥671,735 | CN¥667,790 |
| % Margin | 23% | 21.3% | 27.5% | 28.3% |